Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Sep 11;4(9):e6950.
doi: 10.1371/journal.pone.0006950.

A novel liposome-based adjuvant CAF01 for induction of CD8(+) cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice

Affiliations

A novel liposome-based adjuvant CAF01 for induction of CD8(+) cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice

Gregers Jacob Gram et al. PLoS One. .

Abstract

Background: Specific cellular cytotoxic immune responses (CTL) are important in combating viral diseases and a highly desirable feature in the development of targeted HIV vaccines. Adjuvants are key components in vaccines and may assist the HIV immunogens in inducing the desired CTL responses. In search for appropriate adjuvants for CD8(+) T cells it is important to measure the necessary immunological features e.g. functional cell killing/lysis in addition to immunological markers that can be monitored by simple immunological laboratory methods.

Methodology/principal findings: We tested the ability of a novel two component adjuvant, CAF01, consisting of the immune stimulating synthetic glycolipid TDB (Trehalose-Dibehenate) incorporated into cationic DDA (Dimethyldioctadecylammonium bromide) liposomes to induce CD8(+) T-cell restricted cellular immune responses towards subdominant minimal HLA-A0201-restricted CTL epitopes from HIV-1 proteins in HLA-A*0201 transgenic HHD mice. CAF01 has an acceptable safety profile and is used in preclinical development of vaccines against HIV-1, malaria and tuberculosis.

Conclusions/significance: We found that CAF01 induced cellular immune responses against HIV-1 minimal CTL epitopes in HLA-A*0201 transgenic mice to levels comparable with that of incomplete Freund's adjuvant.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Cellular immune responses are induced to a similar level after immunization with IFA and CAF01.
IFN-γ ELISPOT responses against (A) HLA-A2-restricted CD8 T cell epitope Vif101 and (B) PADRE Th epitope of splenocytes from HLA-A*0201 transgenic HHD mice after 10 days of s.c. immunization with Vif101 and PADRE in either IFA (grey bars, n = 5) or CAF01 adjuvants (black bars, n = 5) and 5 days in vitro prestimulation with individual epitopes. The background of an unimmunized mouse is substracted. Specific 51Cr-release from target cells preloaded with Vif101 after incubation with effector splenocytes from Vif101 and PADRE immunized mice adjuvanted with (C) IFA (grey, n = 5) or (D) CAF01 (black, n = 5). The percentage of specific lysis was calculated as 100×(experimental release-spontaneous release)/(total release-spontaneous release). Background lysis from an unimmunized mouse is shown (open circles). Significant positive levels are considered for >10% lysis at a 50∶1 ratio of effector:target (E:T) cells. One representative experiment out of three. SFU, spot forming units.
Figure 2
Figure 2. Cellular immune responses induced after immunization in CAF01 with or without a T helper epitope.
IFN-γ ELISPOT responses against (A) Vif101 CTL epitope and (B) PADRE Th epitope of splenocytes from HLA-A*0201 transgenic HHD mice after 10 days of s.c. immunization with Vif101 and PADRE (grey bars, n = 5) or with Vif101 alone (black bars, n = 5) and 5 days in vitro prestimulation with individual epitopes. The background of an unimmunized mouse is substracted. Specific 51Cr-release from target cells preloaded with Vif101 after incubation with effector splenocytes from individual mice immunized with (C) Vif101 and PADRE (grey, n = 5) or (D) with Vif101 alone (black, n = 5). The percentage of specific lysis was calculated as 100×(experimental release-spontaneous release)/(total release-spontaneous release). Background lysis from an unimmunized mouse is shown (open circles). Significant levels are considered >10% lysis at a 50∶1 ratio of effector:target (E:T) cells. One representative experiment out of three. SFU, spot forming units.
Figure 3
Figure 3. Proliferative CD8+ T cell responses induced after immunization with IFA and CAF01.
The percentage of proliferating CD3+CD8+ splenocytes (having reduced CFSE dye) derived from HLA-A*0201 transgenic HHD mice 10 days after s.c. immunization with a peptide mix consisting of 10 peptides adjuvanted with (A) IFA or (B) CAF01. The background proliferation of non-stimulated (NS) cells, incubated with media alone is shown. The epitope peptides were (from left to right): NS, Gag150, Gag433, Env67, Pol606, Vpu66, Vif101, Vif23, Gag298 (Th), Env570 (Th) and PADRE (Th).

References

    1. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994;68:6103–6110. - PMC - PubMed
    1. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994;68:4650–4655. - PMC - PubMed
    1. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med. 1999;189:991–998. - PMC - PubMed
    1. Vangala A, Kirby D, Rosenkrands I, Agger EM, Andersen P, et al. A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice. J Pharm Pharmacol. 2006;58:787–799. - PubMed
    1. Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta. 2005;1718:22–31. - PubMed

Publication types

MeSH terms